Cytokinetics Inc (CYTK)

NASD · Healthcare · Biotechnology · USA

Cytokinetics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Cytokinetics discovers and develops small molecule drugs that modulate muscle function for treating cardiovascular and neuromuscular diseases. The company's first approved product is MYQORZO, a cardiac myosin inhibitor authorized by the FDA, European Commission, and China for treating obstructive hypertrophic cardiomyopathy. The company maintains a pipeline of investigational candidates in various development stages.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Cytokinetics Inc stock.

Our verdict on CYTK

Overvalued: intrinsic value $1.04 per share, market price $51.65, margin of safety -4849.9% (as of 2026-11-17).

A 2.4x revenue multiple, discounted for its losses, values the shares at $1.04; the price of $51.65 is 4850% above that value.

ETFs with the most weight in CYTK

17 more funds hold it; the full list is part of the paid plan.

More on CYTK

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than CYTK in Biotechnology

125 more in this industry show a wider margin of safety.

Is CYTK undervalued or overvalued?

CYTK is overvalued (as of the 2026-11-17 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $1.04; the price of $51.65 is 4850% above that value.

What is the intrinsic value of CYTK?

$1.04 per share (as of the 2026-11-17 close), against a market price of $51.65. That is a margin of safety of -4849.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.